Moderna's massive covid vaccine sales and prepayments left it with $18.2 billion in cash at the end of 2022, but that balance is steadily shrinking due to previous share repurchases (more than $5 ...

As the company invests heavily in expanding its non-COVID mRNA vaccine pipeline, the OpenAI partnership positions it to leverage AI’s full potential in accelerating drug development.

Moderna (NASDAQ: MRNA), the next-generation healthcare company most famous for developing the Spikevax coronavirus vaccine, was an uncharacteristically popular stock.

S&P 500 surges in H1 2025; explore AI leaders & ETFs for H2. Click to learn more about stocks to avoid and tips to navigate ...